Skip to main content

Table 3 Multivariate analyses of overall survival in additional independent cases of BRCA, LIHC, LUAD, STAD, and ESCA

From: Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis

Cancer type

Characteristic

Total (cases)

PGK1 pS203

PDHK1 pT338

HR (95% CI)

P

HR (95% CI)

P

BRCA

TNBCa

 No

109

1.000

 

1.000

 

 Yes

24

2.561 (1.205–5.444)

0.014

2.532 (1.191 to 5.383)

0.016

TNM stageb

 I/II

95

1.000

 

1.000

 

 III/IV

48

2.241 (1.172–4.286)

0.015

2.238 (1.174 to 4.265)

0.014

PGK1 pS203

 Low

65

1.000

   

 High

80

1.596 (0.805–3.168)

0.181

  

PDHK1 pT338

 Low

66

  

1.000

 

 High

79

  

1.661 (0.837 to 3.298)

0.147

LIHC

TNM stagec

 I/II

73

1.000

 

1.000

 

 III/IV

104

2.853 (1.878 to 4.335)

0.000

2.905 (1.910 to 4.419)

0.000

PGK1 pS203

 Low

107

1.000

   

 High

78

1.574 (1.064 to 2.327)

0.023

  

PDHK1 pT338

 Low

105

  

1.000

 

 High

80

  

2.060 (1.390 to 3.052)

0.000

LUAD

TNM stage

 I/II

105

1.000

 

1.000

 

 III/IV

74

1.805 (1.267 to 2.570)

0.001

1.828 (1.284 to 2.602)

0.001

PGK1 pS203

 Low

74

1.000

   

 High

105

1.800 (1.238 to 2.617)

0.002

  

PDHK1 pT338

 Low

75

  

1.000

 

 High

104

  

1.634 (1.129 to 2.364)

0.009

STAD

Age (years)

 ≤ 60

56

1.000

 

1.000

 

 > 60

39

2.258 (1.441 to 3.538)

0.000

2.255 (1.436 to 3.540)

0.000

TNM staged

 I/II

24

1.000

 

1.000

 

 III/IV

69

3.382 (1.957 to 5.843)

0.000

3.314 (1.920 to 5.720)

0.000

PGK1 pS203

 Low

51

1.000

   

 High

44

2.603 (1.630 to 4.155)

0.000

  

PDHK1 pT338

 Low

49

  

1.000

 

 High

46

  

2.397 (1.501 to 3.829)

0.000

ESCA

Age (years)

 ≤ 60

112

1.000

 

1.000

 

 > 60

102

1.657 (1.146 to 2.397)

0.007

1.614 (1.114 to 2.338)

0.011

TNM stage

 I/II

98

1.000

 

1.000

 

 III/IV

116

6.041 (3.867 to 9.437)

0.000

6.022 (3.852 to 9.415)

0.000

PGK1 pS203

 Low

103

1.000

   

 High

111

1.440 (0.997 to 2.079)

0.052

  

PDHK1 pT338

 Low

94

  

1.000

 

 High

120

  

1.453 (0.996 to 2.119)

0.053

  1. BRCA breast carcinoma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, STAD stomach adenocarcinoma, ESCA esophageal carcinoma, HR hazard ratio, 95% CI 95% confidence interval, TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, PGK1 pS203 PGK1 S203 phosphorylation level, PDHK1 pT338 PDHK1 T338 phosphorylation level
  2. aThe data of TNBC in BRCA were available in 133 patients
  3. bThe data of TNM stage in BRCA were available in 143 patients
  4. cThe data of TNM stage in LIHC were available in 177 patients
  5. dThe data of TNM stage in STAD were available in 93 patients